Literature DB >> 18585570

Angioedema and angiotensin-converting enzyme inhibitors: are demographics a risk?

Elizabeth J Mahoney1, Anand K Devaiah.   

Abstract

OBJECTIVES: The use of angiotensin-converting enzyme inhibitors (ACEI) has become the leading cause of acquired angioedema. Previous studies have suggested that certain patient populations may be at a higher risk for ACEI-induced angioedema. The objective of this study was to evaluate any demographic associations. STUDY
DESIGN: A retrospective chart review.
MATERIALS AND METHODS: Angioedema patients from 1999 to 2004 treated at a tertiary care hospital were reviewed. Demographics, inciting factors, and comorbid conditions were examined.
RESULTS: One hundred eighty-two patients met inclusion criteria. Sixty-three percent of patients with angioedema had ACEI triggers. Eighty-one percent of all ACEI angioedema occurred in black patients. Of all angioedema patients, 70% (95% confidence interval [CI], 62%-78%) of black patients noted an ACEI as the inciting agent compared with 44% (95% CI, 30%-59%) in other patient groups. Black patients were 3.03 times more likely to have angioedema from an ACEI than all other patient groups (95% CI, 1.54-5.94).
CONCLUSION: This study represents the largest series of patients with angioedema. Although retrospective in nature, the data show that black patients are at a higher risk for ACEI-induced angioedema.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585570     DOI: 10.1016/j.otohns.2008.03.029

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  8 in total

1.  Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record.

Authors:  Aleena Banerji; Kimberly G Blumenthal; Kenneth H Lai; Li Zhou
Journal:  J Allergy Clin Immunol Pract       Date:  2017-04-01

2.  Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors.

Authors:  Seyed H Mahmoudpour; Abirami Veluchamy; Moneeza K Siddiqui; Folkert W Asselbergs; Patrick C Souverein; Catherine E de Keyser; Albert Hofman; Chim C Lang; Alexander S F Doney; Bruno H Stricker; Anthonius de Boer; Anke H Maitland-van der Zee; Colin N A Palmer
Journal:  Pharmacogenet Genomics       Date:  2017-03       Impact factor: 2.089

Review 3.  Factors affecting the development of adverse drug reactions (Review article).

Authors:  Muaed Jamal Alomar
Journal:  Saudi Pharm J       Date:  2013-02-24       Impact factor: 4.330

4.  ACE Inhibitor-Induced Angioedema of the Bowel.

Authors:  Tabitha Campbell; Bradley Peckler; Raleigh David Hackstadt; Austin Payor
Journal:  Case Rep Med       Date:  2010-12-01

5.  Potentially lethal ACE-inhibitor-induced angioedema in a child.

Authors:  Esraa Bukhari; Osama Y Safdar; Mohammed Shalaby; Shafiqa Mj AlSharif; Khoulod Alsufiany; Jameela A Kari
Journal:  Clin Case Rep       Date:  2015-04-09

6.  Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema.

Authors:  Eva Rye Rasmussen; Christian von Buchwald; Mia Wadelius; Sumangali Chandra Prasad; Shailajah Kamaleswaran; Kawa Khaled Ajgeiy; Georg Authried; Kristine Appel U Pallesen; Anette Bygum
Journal:  Int J Otolaryngol       Date:  2017-02-14

Review 7.  Angioedema: Classification, management and emerging therapies for the perioperative physician.

Authors:  Lopa Misra; Narjeet Khurmi; Terrence L Trentman
Journal:  Indian J Anaesth       Date:  2016-08

8.  Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment.

Authors:  Eva Rye Rasmussen; Pär Hallberg; Ekaterina V Baranova; Niclas Eriksson; Malgorzata Karawajczyk; Caroline Johansson; Marco Cavalli; Cyrielle Maroteau; Abirami Veluchamy; Gunilla Islander; Svante Hugosson; Ingrid Terreehorst; Folkert W Asselbergs; Pia Norling; Hans-Erik Johansson; Hugo Kohnke; Ann-Christine Syvänen; Moneeza K Siddiqui; Chim C Lang; Patrik K E Magnusson; Qun-Ying Yue; Claes Wadelius; Christian von Buchwald; Anette Bygum; Ana Alfirevic; Anke H Maitland-van der Zee; Colin N A Palmer; Mia Wadelius
Journal:  Pharmacogenomics J       Date:  2020-02-21       Impact factor: 3.550

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.